HHS Unveils Temporary Policy Allowing Compounding Pharmacies to Make Peptide Products

The U.S. Department of Health and Human Services (HHS) has introduced a new policy that will temporarily permit compounding pharmacies to manufacture certain peptide products. This move is expected to expand patient access to these medications, which are often used in hormone therapy, weight management, and other treatments. The policy comes amid ongoing shortages and regulatory debates surrounding compounded drugs. By easing restrictions, HHS aims to address supply gaps while maintaining safety standards. The decision could reshape the compounding pharmacy landscape and influence future FDA oversight. Stakeholders will be watching how this temporary measure impacts both patient care and the broader pharmaceutical market.